Brain-Computer interface aims to stop epileptic seizures before they start

NCT ID NCT06898138

Not yet recruiting Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This early study at Mayo Clinic tests a new implantable device called the Brain Interchange System in up to 8 people with drug-resistant epilepsy. The device records high-speed brain signals and can deliver targeted electrical stimulation to prevent seizures. Unlike current systems that react after a seizure starts, this one aims to detect warning signals and stop seizures before they happen. For now, the study only checks if the device works as intended, not whether it actually controls seizures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CorTec Brain Interchange System (implantable device for sensing and stimulation)
What this could lead to
If successful, this could pave the way for a future implant that stops seizures before they start, improving seizure control for people with drug-resistant epilepsy.
What could go wrong
This is a very early feasibility study with only 8 participants. It tests whether the device can detect and respond to brain signals, not whether it actually stops seizures. Many technical hurdles remain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Baylor College of Medicine

    Houston, Texas, 77030-3498, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.